Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 622

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 622
---
 including
the transactions described in the section of this Annual Report titled “Certain Relationships and Related Party Transactions.” 

Committees
of the Board of Directors

Our
board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The
functions of these committees are described below. Members will serve on these committees until their resignation or until otherwise
determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from
time to time.

Audit
Committee

The
audit committee was established upon the effectiveness of our initial public offering on February 9, 2024 and consist of Matthew Pratt
Whalen, Edward MacPherson, and Dr. Matt Del Giudice, with Matthew Whalen serving as the chair of the audit committee. Mr. Whalen succeeded
Michael Jerman as Chair of the Audit Committee following Mr. Jerman’s resignation on November 18, 2024. Each member meets the requirements
for independence under the listing standards of Nasdaq and SEC rules and regulations, including Rule 10A-3(b)(1) under the Exchange Act.
Each member of our audit committee meets the financial literacy requirements of the listing standards of Nasdaq. In addition, our board
of directors has determined that Mr. Whalen is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K
under the Securities Act.

58

The
audit committee’s main purpose is to oversee our corporate accounting and financial reporting process. Our audit committee will
be responsible for, among other things:

    ●
    selecting
    a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;

    ●
    helping
    to ensure the independence and performance of the independent registered public accounting firm;

    ●
    discussing
    the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the
    independent registered public accounting firm, our interim and year-end results of operations;

    ●
    developing
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;

    ●
    reviewing
    our policies on risk assessment and risk management;

    ●
    reviewing
    related party transactions;

    ●
    reviewing
    and pre-approving, as required, all audit and all permissible non-audit services to be performed by the independent registered public
    accounting firm; and